

Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules

October 22, 2021

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2021, which covers the results of its business activities for the first nine months of 2021.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2021 amounted to CHF 141 mn (profit of CHF 26 mn in the same period 2020). In the third quarter a loss of CHF 208 mn (loss of CHF 395 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at September 30, 2021 is available under report.bbbiotech.ch/Q321 or www.bbbiotech.com.

For further information:

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech AG is one of the leading investors in this sector. BB Biotech AG builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.